MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

“…One of the most important mechanisms is represented by the inhibition of bcl-w, an antiapoptotic protein of bcl-2 family. High levels of mir-122 down-regulate bcl-w promoting apoptosis (Lin et al, 2008;Young et al, 2010;Xu et al, 2011b). Another important role was demonstrated by Fornari et al (2009).…”

MiR-122 in hepatic function and liver diseases

“…Currently, several target genes of miR-122 have been identified to be involved in hepatocarcinogenesis, such as ADAM10 (a distintegrin and metalloprotease family 10), serum response factor (SRF) (Bai et al, 2009), insulin-like growth factor 1 receptor (Igf1R) (Zeng et al, 2010), cyclin G1 (Fornari et al, 2009), and Wnt1 (Xu et al, 2012). In addition, overexpression and restoration of miR-122 in HCC cells has been shown to sensitize HCC cells to chemotherapeutic agents (Bai et al, 2009;Xu et al, 2011;Yang et al, 2011). Owing to its remarkable tumor inhibitory activity, increasing miR-122 levels may be a promising strategy for HCC treatment .…”

Scutellaria Extract Decreases the Proportion of Side Population Cells in a Myeloma Cell Line by Down-regulating the Expression of ABCG2 Protein

“…We found that adriamycin (doxorubicin), a first-line chemotherapeutant for hematopoietic tumors, did not affect the percentage of SP cells in the MM cell line RPMI-8226, although it showed potent effect on inhibition of cell proliferation. In the present study, we did not examine the effects of adriamycin on cell cycle and cell apoptosis because it has long appreciated that adriamycin can induce DNA damage and arrest cell cycle in various tumors (Di et al, 2008;Marshall et al, 2008;Xu et al, 2011). Therefore, we postulate that adriamycin targets non-SP cells in tumor, which make up of the bulk of tumor, to inhibit the tumor growth and result in clinical remission after treatment with systemic chemotherapy.…”